Project 4 Program Director/Principal Investigator (Last, First, Middle): JoneS, Rlchard J. Allogeneic BMT (alloBMT) is the treatment of choice for eligible patients with hematologic malignancies that are incurable by chemotherapy. Donor T cell mediated graft-versus-tumor effects have the potential to eradicate residual cancer cells that survive pre-transplant cytotoxic therapies. T cell recognition of alloantigens as well as leukemia-associated antigens (LAAs) has been reported to contribute to this effect. Historically, the beneficial impact of allorecognition on relapse-free survival has been largely offset by the toxicities of graft-versus-host-disease (GVHD) and its treatment, and attempts to diminish the latter by donor T cell depletion or recipient immunosuppression have resulted in increased rates of relapse. The studies pioneered in PROJECT 4 have led to the development of high doses of cyclophosphamide.in the early post- BMT period (PT/Cy) as a strategy for generating bi-directional tolerance. As a result, patients treated with PT/Cy have achieved stable hematopoietic engraftment with low rates of GVHD, even in HLA-haploidentical donor/recipient pairs. With this innovation, relapse rather than GVHD is now the major cause of transplant failure. As demonstrated by mouse studies in PROJECT 2, adoptive transfer of lymphocytes from donors primed with a cancer vaccine significantly reduces relapse rates in syngeneic, tumor-bearing recipients. These results led to clinical trials testing the integration of a therapeutic leukemia vaccine into the setting of autologous BMT, which demonstrated that the response to a vaccine administered pirior to graft harvest correlated significantly with post-BMT relapse-free survival. We now propose to evaluate donor vaccination as a strategy to improve the outcome of alloBMT. However, two impediments in bringing donor vaccination into the alloBMT setting are: 1) the risk of inducing autoimmunity in the healthy donor, and 2) the potential to increase the incidence or severity of GVHD. Accordingly, we have chosen to target an antigen that is not expressed in normal tissues of healthy donors, but is aberrantly expressed in many myeloid leukemias. A collaboration between PROJECT 1 and PROJECT 2 has led to the discovery that PRAME, a cancer testis antigen, is one of the few identified LAAs that is abundantly expressed in leukemic stem cells (LSCs), but is absent from normal hematopoietic stem cells. This proposal seeks to link these three fundamental discoveries in GVHD prophylaxis (Project 4), adoptive transfer of vaccine pnmed immunity (Project 2), and LSC antigen expression (Project 1) to improve the outcome of alloBMT.
With newer procedures for reducing the morbidity and mortality of alloBMT, the major cause of transplant failure is relapse. This proposal addresses this limitation by studying vaccination of healthy BMT donors against a leukemia-associated antigen, so as to transfer immune cells capable of killing residual leukemia in the patient. The proposal also studies shortening the duration of pharmacologic immunosuppression so as to facilitate the timely application of post-transplantation immunotherapy.
|Robinson, Tara M; O'Donnell, Paul V; Fuchs, Ephraim J et al. (2016) Haploidentical bone marrow and stem cell transplantation: experience with post-transplantation cyclophosphamide. Semin Hematol 53:90-7|
|Kanakry, Christopher G; Fuchs, Ephraim J; Luznik, Leo (2016) Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol 13:10-24|
|Robinson, Tara M; Fuchs, Ephraim J (2016) Allogeneic stem cell transplantation for sickle cell disease. Curr Opin Hematol 23:524-529|
|DeZern, Amy E; Williams, Katherine; Zahurak, Marianna et al. (2016) Red blood cell transfusion triggers in acute leukemia: a randomized pilot study. Transfusion 56:1750-7|
|Gerber, Jonathan M; Zeidner, Joshua F; Morse, Sarah et al. (2016) Association of acute myeloid leukemia's most immature phenotype with risk groups and outcomes. Haematologica 101:607-16|
|Lombardi, Lindsey R; Kanakry, Christopher G; Zahurak, Marianna et al. (2016) Therapeutic drug monitoring for either oral or intravenous busulfan when combined with pre- and post-transplantation cyclophosphamide. Leuk Lymphoma 57:666-75|
|Gondek, L P; Zheng, G; Ghiaur, G et al. (2016) Donor cell leukemia arising from clonal hematopoiesis after bone marrow transplantation. Leukemia 30:1916-20|
|Kanakry, Christopher G; Coffey, David G; Towlerton, Andrea M H et al. (2016) Origin and evolution of the T cell repertoire after posttransplantation cyclophosphamide. JCI Insight 1:|
|Alonso, Salvador; Hernandez, Daniela; Chang, Yu-Ting et al. (2016) Hedgehog and retinoid signaling alters multiple myeloma microenvironment and generates bortezomib resistance. J Clin Invest 126:4460-4468|
|Kanakry, Christopher G; Fuchs, Ephraim J; Luznik, Leo (2016) Modern approaches to HLA-haploidentical blood or marrow transplantation. Nat Rev Clin Oncol 13:132|
Showing the most recent 10 out of 436 publications